Research programme: antibody-drug conjugates - ImmunoGen

Drug Profile

Research programme: antibody-drug conjugates - ImmunoGen

Alternative Names: Anti-ADAM9 antibody-drug conjugates; anti-CD123 ADC - Immunogen; Anti-CD33-3m; Anti-CD56-3m; Anti-cMet antibody-drug conjugate; Anti-cMet-DGN549; Anti-EGFR-3m; Anti-FRα-3m; CD19-targeting antibody-drug conjugate; huB4-DGN462; IGN P1; IGNs-ADCs; M-DGN549; M9346A NL DM

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator ImmunoGen
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action ADAM9 protein modulators; Alkylating agents; CD19 antigen inhibitors; CD33 antigen inhibitors; CD56 antigen inhibitors; DNA cross linking agents; Epidermal growth factor receptor antagonists; Folate receptor 1 antagonists; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 Nov 2016 Preclinical data of M DGN 549 presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(EORTC-NCI-AACR-2016)
  • 14 Apr 2016 Pharmacodynamics, adverse events and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top